Annual ROA
-41.10%
+1.96%+4.55%
December 31, 2023
Summary
- As of February 8, 2025, VYNE annual return on assets is -41.10%, with the most recent change of +1.96% (+4.55%) on December 31, 2023.
- During the last 3 years, VYNE annual ROA has risen by +254.51% (+86.10%).
- VYNE annual ROA is now -291.43% below its all-time high of -10.50%, reached on December 31, 2015.
Performance
VYNE ROA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly ROA
-45.76%
-1.38%-3.11%
September 30, 2024
Summary
- As of February 8, 2025, VYNE quarterly return on assets is -45.76%, with the most recent change of -1.38% (-3.11%) on September 30, 2024.
- Over the past year, VYNE quarterly ROA has dropped by -1.38% (-3.11%).
- VYNE quarterly ROA is now -297.91% below its all-time high of -11.50%, reached on December 31, 2016.
Performance
VYNE Quarterly ROA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
ROA Formula
ROA = Net Income
Total Assets ✕ 100%
Total Assets ✕ 100%
VYNE ROA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +4.5% | -3.1% |
| 3 y3 years | +86.1% | -8.1% |
| 5 y5 years | +17.4% | -8.1% |
VYNE ROA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +54.9% | -16.0% | +52.5% |
| 5 y | 5-year | at high | +86.1% | -16.0% | +79.5% |
| alltime | all time | -291.4% | +86.1% | -297.9% | +79.5% |
VYNE Therapeutics ROA History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | -45.76%(+3.1%) |
| Jun 2024 | - | -44.38%(-17.9%) |
| Mar 2024 | - | -54.08%(-17.2%) |
| Dec 2023 | -41.10%(-4.6%) | -65.28%(-32.2%) |
| Sep 2023 | - | -96.34%(+11.5%) |
| Jun 2023 | - | -86.38%(+25.0%) |
| Mar 2023 | - | -69.09%(+63.3%) |
| Dec 2022 | -43.06%(-52.8%) | -42.32%(+7.3%) |
| Sep 2022 | - | -39.45%(-13.5%) |
| Jun 2022 | - | -45.61%(-6.0%) |
| Mar 2022 | - | -48.51%(-30.5%) |
| Dec 2021 | -91.21%(-69.1%) | -69.80%(-7.0%) |
| Sep 2021 | - | -75.05%(+4.5%) |
| Jun 2021 | - | -71.80%(-60.9%) |
| Mar 2021 | - | -183.72%(-17.8%) |
| Dec 2020 | -295.61% | -223.41%(+1.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2020 | - | -220.85%(+4.4%) |
| Jun 2020 | - | -211.54%(+156.8%) |
| Mar 2020 | - | -82.39%(+24.4%) |
| Dec 2019 | -67.28%(+35.2%) | -66.24%(+20.0%) |
| Sep 2019 | - | -55.21%(+17.9%) |
| Jun 2019 | - | -46.83%(+24.8%) |
| Mar 2019 | - | -37.51%(+3.4%) |
| Dec 2018 | -49.75%(-6.8%) | -36.27%(+8.5%) |
| Sep 2018 | - | -33.43%(+6.5%) |
| Jun 2018 | - | -31.39%(-6.7%) |
| Mar 2018 | - | -33.66%(-28.7%) |
| Dec 2017 | -53.39%(+59.6%) | -47.22%(+12.9%) |
| Sep 2017 | - | -41.81%(+6.8%) |
| Jun 2017 | - | -39.15%(+59.7%) |
| Mar 2017 | - | -24.52%(+113.2%) |
| Dec 2016 | -33.45%(+218.6%) | -11.50% |
| Dec 2015 | -10.50% | - |
FAQ
- What is VYNE Therapeutics annual return on assets?
- What is the all time high annual ROA for VYNE Therapeutics?
- What is VYNE Therapeutics annual ROA year-on-year change?
- What is VYNE Therapeutics quarterly return on assets?
- What is the all time high quarterly ROA for VYNE Therapeutics?
- What is VYNE Therapeutics quarterly ROA year-on-year change?
What is VYNE Therapeutics annual return on assets?
The current annual ROA of VYNE is -41.10%
What is the all time high annual ROA for VYNE Therapeutics?
VYNE Therapeutics all-time high annual return on assets is -10.50%
What is VYNE Therapeutics annual ROA year-on-year change?
Over the past year, VYNE annual return on assets has changed by +1.96% (+4.55%)
What is VYNE Therapeutics quarterly return on assets?
The current quarterly ROA of VYNE is -45.76%
What is the all time high quarterly ROA for VYNE Therapeutics?
VYNE Therapeutics all-time high quarterly return on assets is -11.50%
What is VYNE Therapeutics quarterly ROA year-on-year change?
Over the past year, VYNE quarterly return on assets has changed by -1.38% (-3.11%)